Compare HBCP & VOGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HBCP | VOGX |
|---|---|---|
| Founded | 1908 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 529.0M | 482.8M |
| IPO Year | 2008 | 2026 |
| Metric | HBCP | VOGX |
|---|---|---|
| Price | $61.91 | $19.73 |
| Analyst Decision | Hold | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $68.00 | N/A |
| AVG Volume (30 Days) | 69.0K | ★ 73.2K |
| Earning Date | 10-19-2026 | 11-19-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | ★ 29.01 | N/A |
| EPS | ★ 2.93 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.94 | N/A |
| Revenue Next Year | $4.51 | N/A |
| P/E Ratio | $20.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $52.07 | $13.50 |
| 52 Week High | $74.50 | $38.41 |
| Indicator | HBCP | VOGX |
|---|---|---|
| Relative Strength Index (RSI) | 36.78 | 53.58 |
| Support Level | $56.77 | $14.61 |
| Resistance Level | $65.53 | $22.10 |
| Average True Range (ATR) | 1.85 | 2.63 |
| MACD | 0.01 | 0.71 |
| Stochastic Oscillator | 41.06 | 78.60 |
Home Bancorp Inc is engaged in attracting deposits from the public and using those funds to invest in loans and securities.It is holding company for Home Bank, N.A. The principal sources of funds are customer deposits, repayments of loans, repayments of investments, and funds borrowed from outside sources such as the Federal Home Loan Bank of Dallas. These funds are used for the origination of loans, including one-to-four-family first mortgage loans, home equity loans, and lines, commercial real estate loans, construction and land loans, multi-family residential loans, commercial and industrial loans, and consumer loans.
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.